Psychiatric NP Scope of Practice for Insomnia in Georgia

You’re a psychiatrist or PMHNP who knows you can help patients with insomnia. The patient needs care, you have the expertise, and telehealth makes it accessible. But then the question hits: Can I legally prescribe Ambien via video visit? What about controlled substances? Will my state medical board come after me?

Here’s the reality: Yes, you can prescribe insomnia medications via telehealth in 2025–2026 — including Schedule IV controlled substances like zolpidem (Ambien), eszopiclone (Lunesta), and benzodiazepines. The DEA’s current temporary rules, extended through December 31, 2026, allow you to prescribe these medications after a telehealth evaluation without an in-person exam.

But — and this is where it gets tricky — your state’s rules matter just as much as federal law. Florida requires you to document insomnia as a psychiatric disorder. Texas bans telehealth prescribing for chronic pain (but not insomnia). Pennsylvania mandates PDMP checks for every benzodiazepine prescription. And if you’re an PMHNP? Your prescriptive authority depends entirely on whether you’re practicing in New York (full independence after 3,600 hours), Texas (physician supervision required), or somewhere in between.

This guide breaks down what you actually need to know: the current federal rules, how each major state handles telehealth prescribing for insomnia, what’s different for psychiatrists vs PMHNPs, and what changes are coming in 2026–2027.

The Federal Framework: DEA Telehealth Rules and the Ryan Haight Act

What the Ryan Haight Act Normally Requires

Under the Ryan Haight Online Pharmacy Act of 2008, prescribing controlled substances ‘via the internet’ requires at least one in-person medical evaluation. This law was passed to shut down illegal online pill mills — but it also technically blocked legitimate telehealth providers from prescribing medications like Ambien or temazepam without seeing patients face-to-face first.

For insomnia providers pre-2020, this meant: see the patient in person once, then you could manage them via telehealth and refill their controlled sleep medications. Alternatively, use only non-controlled options (like trazodone or ramelteon) for pure telehealth patients.

COVID-Era Waivers Changed Everything

When the COVID-19 public health emergency hit, DEA suspended the in-person requirement. Starting March 2020, DEA-registered practitioners could prescribe Schedule II–V controlled substances via telehealth without any prior in-person visit, as long as the prescription was for a legitimate medical purpose and complied with state law.

This opened the floodgates for telehealth mental health care — and it’s why platforms offering online insomnia treatment exploded during the pandemic.

Current Status: Extended Through 2026

The DEA has repeatedly extended these flexibilities. Most recently, on December 31, 2025, the agency announced a fourth extension through December 31, 2026. This means:

• You can prescribe Schedule IV insomnia medications (zolpidem, eszopiclone, temazepam, etc.) after a live audio-video telemedicine evaluation
• No in-person exam is required federally
• You must still meet standard of care, maintain DEA registration, and comply with all state laws
• Audio-only is permitted for FDA-approved buprenorphine treatment but generally not for other controlled substances (use video)

The catch: These are temporary rules. The DEA has proposed a permanent framework involving ‘Special Registration’ for telemedicine prescribing, expected to take effect before 2027. Under the proposed rules:

• Schedule III–V medications (which includes most insomnia drugs): Any DEA-registered provider could prescribe via telehealth with a ‘Telemedicine Special Registration’
• Schedule II medications: Only certain specialists (including psychiatrists) would qualify for an ‘Advanced Telemedicine Registration’ to prescribe stimulants or other Schedule II drugs online
• A national PDMP system would provide additional oversight

For now, you operate under the temporary extension. But expect new requirements — likely including that special registration and possibly an eventual mandate for at least one in-person visit for ongoing controlled substance treatment.

What This Means Practically

If you’re treating insomnia via telehealth in 2025–2026:

1. You can prescribe Schedule IV sleep medications after an appropriate telehealth evaluation
2. Standard DEA rules still apply: You need a DEA number, must prescribe within your scope, and follow state-specific controlled substance laws
3. Documentation matters: Treat the telehealth visit like an in-person visit. Document your assessment, diagnosis, treatment rationale, and patient education
4. PDMP checks: Most states now require checking the prescription drug monitoring program before prescribing controlled substances
5. E-prescribing: Many states mandate electronic prescribing for controlled substances

The federal government is effectively saying: ‘We trust you to practice good medicine via telehealth, but we’re watching, and permanent rules are coming.’

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Insomnia Medications: What You’re Actually Prescribing

Let’s be clear about what we’re talking about when we say ‘insomnia medications’ from a regulatory standpoint.

Common Controlled Insomnia Medications (Schedule IV)

Most prescription insomnia treatments are Schedule IV controlled substances:

• Non-benzodiazepine hypnotics (‘Z-drugs’): Zolpidem (Ambien), eszopiclone (Lunesta), zaleplon — the go-to first-line medications for insomnia
• Benzodiazepines: Temazepam (Restoril), triazolam — effective but carry tolerance/dependence risks with long-term use
• Orexin receptor antagonists: Suvorexant (Belsomra), lemborexant — newer class, still Schedule IV federally

Schedule IV means:

• Lower abuse potential than Schedule II (opioids, stimulants) or III
• Can be refilled up to 5 times within 6 months
• DEA registration required to prescribe
• Subject to state PDMP monitoring
• Must be prescribed for legitimate medical purposes in usual course of professional practice

Non-Controlled Alternatives

Several insomnia treatments are not controlled substances and therefore don’t trigger the Ryan Haight Act or most state telehealth prescribing restrictions:

• Off-label antidepressants: Trazodone, doxepin (low-dose) — commonly used, no controlled substance issues
• Melatonin receptor agonists: Ramelteon (Rozerem) — not controlled
• Antihistamines: Diphenhydramine, doxylamine — over-the-counter, but sometimes prescribed

If you’re nervous about controlled substance regulations, these options let you treat insomnia via telehealth with zero federal or state restrictions beyond normal prescribing standards.

Why Schedule IV Status Matters for Telehealth

Schedule IV is the sweet spot for telehealth insomnia care:

• Not Schedule II: You avoid the strictest state restrictions (many states ban or heavily restrict Schedule II telehealth prescribing)
• Not opioids: You sidestep opioid-specific laws like mandatory prescription limits, special patient agreements, or pain management clinic registration
• Lower risk profile: Medical boards are less likely to scrutinize Schedule IV sedative-hypnotic prescribing compared to opioids or stimulants (though over-prescribing benzodiazepines can still draw attention)

The main regulatory concerns with Schedule IV insomnia meds:

1. Dependency risk: Benzodiazepines especially — document your rationale for continued use beyond short-term
2. PDMP monitoring: Most states require checking for doctor-shopping or concurrent prescriptions
3. Standard of care: Make sure you’ve ruled out sleep apnea, tried behavioral approaches (or at least discussed CBT-I), and aren’t just handing out pills

Psychiatrists vs PMHNPs: Who Can Prescribe What

This is where state law creates dramatic differences in what you can actually do.

Psychiatrists: Full Scope, No Supervision Required

If you’re a psychiatrist (MD or DO), your scope of practice is straightforward:

Federal level: You have full prescriptive authority for all controlled substances (Schedule II–V) as part of your medical license and DEA registration.

State level: Every state allows psychiatrists to diagnose and treat insomnia, prescribe any insomnia medication (controlled or non-controlled), and provide this care via telehealth as long as you:

• Hold a valid medical license in the state where the patient is located
• Meet the standard of care for diagnosis and treatment
• Comply with state-specific telehealth and prescribing regulations (PDMP checks, e-prescribing, etc.)

No supervision or collaboration required. You don’t need a physician partner, you don’t need anyone to review your charts, and you don’t need permission to prescribe controlled substances.

The only limitation: You must be licensed in the state where you’re treating patients. Interstate telehealth requires either individual state licenses or participation in the Interstate Medical Licensure Compact (IMLC), which 40 states have joined to expedite multi-state licensure.

PMHNPs: It Depends Entirely on Your State

If you’re a psychiatric mental health nurse practitioner, your ability to independently prescribe insomnia medications varies dramatically by state. There are three categories:

Full Practice Authority States

Examples: New York (after 3,600 hours), Illinois (after 4,000 hours + FPA application), California (transitioning)

In these states, experienced PMHNPs can:

• Practice completely independently without physician oversight
• Prescribe all medications including controlled substances (with separate DEA registration)
• Open their own telehealth practice
• Manage insomnia patients from evaluation through ongoing medication management

New York specifics: After completing 3,600 hours of practice under a collaborative agreement (roughly 2 years full-time), you can practice and prescribe independently. The NP Modernization Act made this permanent in 2022. You’ll still need to check the I-STOP PDMP before every controlled substance prescription and use e-prescribing.

Illinois specifics: After 4,000 hours of practice and additional continuing education in your specialty, you can apply for Full Practice Authority. This includes independent prescribing of controlled substances (with a separate FPA-controlled substance license). There’s a consultation requirement for complex cases and for long-term Schedule II prescribing, but this rarely affects insomnia care (mostly Schedule IV).

Reduced Practice States

Examples: Pennsylvania, New York (for new NPs)

In these states, you can practice with substantial autonomy but you must have a collaborative agreement with a physician:

• The physician doesn’t need to see your patients or co-sign every prescription
• The agreement must specify your prescriptive authority (usually includes Schedule III–V)
• You need periodic chart reviews and physician availability for consultation
• You can manage insomnia independently within the agreement’s scope

Pennsylvania specifics: All NPs need a collaborative agreement with a physician to practice and prescribe. The agreement must detail what medications you can prescribe. You’ll need to check the ABC-MAP PDMP before every benzodiazepine prescription (first fill and all refills) — this is stricter than most states.

Restricted Practice States

Examples: Texas, Florida (for psychiatric NPs)

In these states, you need direct physician supervision or delegation:

Texas: You must have a Prescriptive Authority Agreement with a supervising physician. You cannot prescribe Schedule II controlled substances in outpatient settings at all. You can prescribe Schedule IV insomnia medications with delegation. Texas law requires periodic meetings with your supervising physician (can be virtual) to review cases. You must check the Texas PDMP before prescribing benzodiazepines or other specified controlled substances.

Florida: Psychiatric NPs still require a supervising physician protocol (though Florida created an ‘autonomous APRN’ license in 2020, it explicitly excluded psychiatric NPs). You can prescribe Schedule IV insomnia medications under your supervising physician’s protocol. Here’s the Florida trick: The state prohibits telehealth prescribing of controlled substances except for treating psychiatric disorders, inpatient care, hospice, or nursing homes. As long as you document insomnia as a psychiatric disorder (which it is — DSM-5 Insomnia Disorder), you’re legally covered.

The Bottom Line for Provider Type

• Psychiatrists: You have maximum flexibility. Get licensed in your target states, follow federal and state controlled substance laws, and you’re good to go.

• PMHNPs: Research your state’s scope of practice laws before launching a telehealth insomnia practice. If you’re in a full-practice state (or will qualify soon), you can operate independently. If you’re in a restricted state, you’ll need to either practice under a supervising physician or consider getting licensed in multiple full-practice states to expand your patient base.

State-by-State Breakdown: Where the Rules Actually Matter

Federal law sets the floor. State law determines whether you can actually practice.

California

Licensing: Must hold full California license (no special telehealth license available). Not in IMLC, so out-of-state psychiatrists must go through standard CA licensure process.

NP Independence: California’s AB 890 (implemented 2023) allows experienced NPs (with 3+ years under physician oversight) to practice independently. A PMHNP can manage insomnia cases solo after meeting these requirements.

Telehealth Prescribing: No state prohibition on prescribing Schedule IV via telehealth. Schedule II via telehealth is technically discouraged without a prior in-person exam, but this doesn’t affect insomnia care (which uses Schedule IV). California law requires an ‘appropriate prior examination’ before prescribing controlled substances — this can be done via telehealth if it meets the standard of care.

PDMP: Mandatory CURES check before the first prescription of any Schedule II–IV controlled substance and at least every 4 months for ongoing therapy. So check CURES before prescribing Ambien, then again if the patient continues beyond 4 months.

E-Prescribing: Mandatory for all controlled substances as of 2022 (few exceptions).

Economic Reality: High demand, especially in rural areas. Strong telehealth parity laws mean insurance covers telehealth visits at par with in-person. Large, diverse population creates opportunity but also means competition in major metros.

Texas

Licensing: Part of IMLC for physicians. APRNs need full Texas license plus supervising physician agreement.

NP Independence: None. PMHNPs require written Prescriptive Authority Agreement with a Texas physician. One physician can supervise up to 7 NPs. NPs cannot prescribe Schedule II in outpatient settings at all.

Telehealth Prescribing: Here’s the critical Texas rule: Prohibited to prescribe controlled substances via telehealth for chronic pain management. This ban does not apply to insomnia (insomnia is not chronic pain). You can legally prescribe Schedule IV sleep medications via telehealth in Texas.

PDMP: Must check Texas PMP AWARxE before prescribing opioids, benzodiazepines, barbiturates, or (as of 2021) any Schedule III–V drugs. This means check before prescribing temazepam or even zolpidem.

E-Prescribing: Mandatory for controlled substances as of 2021.

Economic Reality: Large market (especially underserved rural areas), but physician supervision requirement limits NP-led insomnia care. Psychiatrists have an advantage here. Strong military/veteran presence means potential patient base with high insomnia prevalence.

Florida

Licensing: Unique option — out-of-state providers can register as Florida telehealth providers without full licensure. Otherwise, need FL license or use IMLC (for physicians).

NP Independence: Restricted for psychiatric NPs. Despite 2020 law creating autonomous APRN license, psychiatric NPs were excluded. You need supervising physician protocol. (Note: 2025 legislation proposed expanding autonomy to psych NPs, but not yet passed as of early 2026.)

Telehealth Prescribing: This is where Florida gets interesting. State law prohibits telehealth prescribing of controlled substances except for four scenarios: (1) treating psychiatric disorders, (2) inpatient care, (3) hospice, or (4) nursing homes.

For insomnia care, you’re covered under the psychiatric disorder exception — insomnia disorder is a recognized mental health condition (DSM-5). Document it as such. Don’t frame it purely as a medical sleep disorder; emphasize the psychiatric/behavioral components.

PDMP: Must check E-FORCSE before every controlled substance prescription to patients age 16+. Not just first fill — every single prescription.

E-Prescribing: Required for controlled substances.

Economic Reality: Large elderly population with high insomnia prevalence. Snowbird population creates telehealth opportunities. Out-of-state telehealth registration is a unique advantage. Supervising physician requirement for NPs creates barrier but not insurmountable. Document the psychiatric angle carefully to stay within telehealth prescribing exception.

New York

Licensing: Must hold NY license (no telehealth-specific license, not in IMLC).

NP Independence: Full practice after 3,600 hours. New NPs must practice under written collaborative agreement with physician until completing 3,600 hours of supervised practice (about 2 years full-time). After that, can practice and prescribe completely independently. NP Modernization Act made this permanent in 2022.

Telehealth Prescribing: No state restrictions on controlled substance prescribing via telehealth beyond federal requirements. Standard of care must be met via telehealth (just like in-person).

PDMP: Mandatory I-STOP check before every prescription of Schedule II, III, or IV controlled substances. Every. Single. Time. Not just initial — every refill, every new prescription. This is stricter than most states.

E-Prescribing: Mandatory for all prescriptions (with very limited exceptions).

Economic Reality: High demand in both NYC (where provider availability is better but demand is enormous) and upstate rural areas (provider shortages). Strong telehealth parity laws and Medicaid coverage. The path to NP independence creates opportunity for experienced PMHNPs to build solo practices. Strict PDMP compliance is non-negotiable.

Pennsylvania

Licensing: In IMLC for physicians. No telehealth-specific license; attempts at comprehensive telehealth legislation ongoing but not yet passed.

NP Independence: None. PMHNPs need collaborative agreement with physician to practice and prescribe. No independent practice path currently available (legislative efforts have not succeeded as of 2026).

Telehealth Prescribing: No additional state barriers beyond federal requirements. Standard of care via telemedicine enforced by medical and nursing boards, but no special telehealth prescribing statute.

PDMP: Must query PA ABC-MAP PDMP before initially prescribing any opioid or benzodiazepine, and for every subsequent prescription or refill of opioids or benzos. This means every time you prescribe temazepam or any benzo for sleep, check the PDMP. Good practice to check for other controlled substances (like zolpidem) as well, even though not explicitly mandated.

E-Prescribing: Strongly encouraged, effectively required in most healthcare systems.

Economic Reality: Urban centers (Philly, Pittsburgh) well-served, but rural central and Appalachian Pennsylvania underserved. Telehealth fills gaps. Collaborative agreement requirement for NPs creates administrative barrier. Standard practice otherwise — just follow the PDMP rules meticulously for benzos.

Illinois

Licensing: In IMLC for physicians. APRNs need Illinois license (not in APRN Compact).

NP Independence: Full Practice Authority available. APRNs can apply for FPA after 4,000 hours of practice plus additional continuing education in specialty. Once granted, can practice and prescribe (including controlled substances) completely independently. Without FPA, need written collaborative agreement with physician.

Telehealth Prescribing: No state-specific restrictions. Provider-patient relationship can be established via telehealth. Standard prescribing criteria apply. Illinois Telehealth Act (2021 update) ensured permanent audio-only mental health coverage and parity protections.

PDMP: Must attempt PMP check before prescribing controlled substances. As of 2018, mandatory for initial opioid prescriptions. Strongly encouraged for all Schedule IV, though not technically mandatory for non-opioids.

E-Prescribing: Mandated for controlled substances in line with 2023 federal Medicare requirements.

Economic Reality: Chicago area has provider concentration but huge demand. Downstate Illinois faces shortages — telehealth critical. Progressive NP laws (FPA) and strong telehealth support create favorable environment. State focus has been on opioid safety; for insomnia meds, regulators not particularly restrictive beyond standard monitoring.

The Economics: Why This Matters for Your Practice

Let’s talk about the business reality of telehealth insomnia care — because understanding the regulations is pointless if you can’t build a sustainable practice.

The DIY Marketing Trap

Many providers think: ‘I’ll just build my own telehealth practice. Get a website, run some Google Ads, list on Psychology Today, and patients will come.’

Reality check: Acquiring qualified psychiatric patients through DIY marketing typically costs $200–500+ per patient when you account for:

• Agency or consultant fees for managing SEO/PPC campaigns
• Months of SEO investment (6–12 months minimum) before seeing results
• Google Ads costs ($15–40+ per click for mental health keywords, most don’t convert)
• Staff time to qualify leads and handle scheduling
• No-show rates from cold leads
• Failed campaigns and testing costs
• Directory listing fees (Psychology Today charges monthly; Zocdoc charges per booking on top of subscription)

The bigger problem: You don’t have 6–12 months to wait for SEO results while you’re trying to fill your schedule. And you probably don’t have $3,000–5,000/month to gamble on marketing channels that may or may not work.

The Platform Advantage

This is where a platform model (like Klarity Health) changes the economics entirely:

Pay only when you see patients: Instead of upfront marketing spend, you pay a standard fee per new patient booking. No wasted ad spend on clicks that don’t convert. No monthly subscriptions you’re paying whether you see patients or not.

Pre-qualified patients: Patients come to you already matched to your specialty (insomnia, ADHD, depression, etc.) and your availability. They’re not just clicking an ad — they’re specifically seeking insomnia treatment and ready to book.

Built-in infrastructure: You get the telehealth platform, EHR, e-prescribing, scheduling, patient communication — none of which you pay for separately. No $200–300/month telehealth software subscription. No separate HIPAA-compliant communication tools.

Both insurance and cash-pay flow: Access to both revenue streams without having to negotiate individual payer contracts or build separate cash-pay marketing.

Schedule control: You decide when you’re available. See 5 patients a week or 25. Take a month off. No monthly fees when you’re not working.

The ROI difference: Let’s say you invest $5,000 in marketing in month 1 of a DIY practice. If you’re lucky, you might see 3–5 new patients that month. That’s $1,000+ per patient acquired, and you still have all your other overhead (malpractice, licensing, platform costs, admin time).

With a pay-per-appointment model, every dollar you spend directly results in a patient visit. That’s guaranteed ROI vs gambling on whether your Google Ads will convert.

When DIY Makes Sense

To be fair: If you have the budget ($5,000–10,000), expertise (or hire experts), and patience (6–12 months), DIY marketing can eventually become cost-effective at scale. If you’re an established practice adding telehealth, or a psychiatrist who can command $300+ per hour cash-pay rates, the investment might pay off.

But for most providers — especially PMHNPs starting out, psychiatrists transitioning to telehealth, or anyone who needs patient flow now — the platform model removes all the risk.

What’s Changing in 2026–2027: Prepare Now

The DEA’s current extension runs through December 31, 2026. Here’s what’s likely coming:

Special Registration Requirements

The DEA’s proposed permanent rules will likely require:

• Telemedicine Special Registration: A new credential to prescribe Schedule III–V drugs via telehealth (covers most insomnia meds)
• Advanced Telemedicine Registration: For psychiatrists and certain specialists to prescribe Schedule II drugs online
• National PDMP integration: Enhanced monitoring across states

What this means: You’ll probably need to apply for and maintain an additional federal registration (beyond your standard DEA number) to continue telehealth prescribing. Expect fees and potentially continuing education requirements.

Possible Return of In-Person Requirements

One scenario: The final rules could mandate at least one in-person visit within the first year of ongoing controlled substance treatment via telehealth. This would mean:

• Initial telehealth visit and prescription allowed
• Ongoing treatment requires in-person exam within 12 months
• Hybrid model becomes standard

This isn’t confirmed, but it’s been discussed in DEA proposals. If you’re building a telehealth-only practice, have a plan for either:

• Partnering with local providers who can do in-person visits
• Opening limited brick-and-mortar availability
• Focusing on non-controlled insomnia treatments that won’t be affected

State-Level Changes to Watch

• Florida: Proposed SB 758 would grant psychiatric NPs autonomous practice authority. If it passes, Florida becomes much more favorable for PMHNP-led insomnia care.
• Texas: Ongoing legislative discussions about expanding NP scope of practice (unlikely to change dramatically, but watch for updates)
• California: Full implementation of AB 890 NP independence — more experienced NPs qualifying for solo practice through 2026
• Pennsylvania: Continued efforts to pass comprehensive telehealth legislation and NP independence bills

How to Prepare

1. Document everything now: Establish strong documentation practices that will meet any future standard of care requirements
2. Build state-specific protocols: Don’t use generic templates — tailor your evaluation and prescribing approach to each state’s current rules
3. Stay current on PDMP requirements: These are expanding, not contracting. Make PDMP checks part of your routine workflow
4. Plan for Special Registration: Set aside budget and time for the DEA’s new registration process when it launches
5. Consider multi-state licensure: If you’re relying on one state, you’re vulnerable to rule changes. Diversify your licensure portfolio.

How to Actually Start Treating Insomnia Via Telehealth

If you’re ready to add telehealth insomnia care to your practice (or launch a new telehealth focus), here’s the practical roadmap:

1. Get Your Regulatory Foundation Right

Licensing:

• Obtain licenses in states where you’ll treat patients (start with 1–2 high-demand states)
• For physicians: Consider IMLC to streamline multi-state licensing
• For NPs: Check whether you need collaborative agreements in each state

DEA Registration:

• Maintain current DEA registration
• If practicing in multiple states, ensure your DEA registration covers all locations

State Controlled Substance Licenses:

• Many states require separate state-level controlled substance registration (beyond DEA)
• Example: Illinois ICS number, New York state registration

Malpractice Insurance:

• Verify your policy covers telehealth
• Verify coverage extends to all states where you’re licensed
• Consider higher limits if practicing solo

2. Set Up Your Clinical Protocols

Evaluation Process:

• Standard sleep history (onset, duration, frequency of insomnia)
• Screen for sleep apnea (Epworth Sleepiness Scale, STOP-BANG questionnaire)
• Rule out medical causes (thyroid, chronic pain, medication side effects)
• Psychiatric comorbidities (depression, anxiety — common with insomnia)
• Prior treatments tried (behavioral, OTC, previous prescriptions)
• Substance use history (alcohol, cannabis, other sedatives)

Documentation Requirements:

• DSM-5 diagnosis (Insomnia Disorder, specify if comorbid)
• Clinical rationale for controlled substance if prescribed
• Discussion of non-pharmacological options (CBT-I, sleep hygiene)
• Patient education on medication (expectations, risks, dependency potential)
• PDMP check results (document date, findings, clinical decision-making)
• Follow-up plan

PDMP Integration:

• Integrate PDMP checking into your workflow before prescribing
• Know your state’s specific requirements (every prescription vs. initial only)
• Document any red flags found (multiple prescribers, early refills) and your response

Prescribing Approach:

• Start with lowest effective dose
• Short-term use (4 weeks) for acute insomnia
• Intermittent dosing for chronic insomnia (not nightly if possible)
• Regular re-evaluation of need
• Taper plan if discontinuing benzodiazepines

3. Choose Your Practice Model

Option A: Join a Platform (Klarity Health Model)

Pros:

• Zero upfront marketing costs
• Immediate patient flow
• Built-in telehealth/EHR/e-prescribing infrastructure
• Compliance support and state-specific guidance
• Pay only when you see patients
• Work your own schedule

Cons:

• Per-appointment fee reduces your take-home per visit
• Less control over patient acquisition and marketing
• Platform’s brand, not yours

Best for: Providers who want to focus on clinical care, need income quickly, or don’t want to handle business operations.

Option B: Build Your Own Practice

Pros:

• Keep 100% of revenue
• Build your own brand
• Total control over patient selection and practice style
• Can scale into group practice over time

Cons:

• $5,000–10,000+ upfront investment
• 6–12 months before meaningful patient flow
• Ongoing marketing costs ($2,000–5,000/month)
• You handle all administrative/tech/compliance yourself
• Much higher risk of failure

Best for: Established providers adding telehealth, psychiatrists with capital to invest, or those with business/marketing expertise.

Option C: Hybrid Model

Start with a platform to build cash flow and patient volume, then gradually build your own direct-to-patient marketing while maintaining platform relationships as a patient source.

4. Set Your Financial Targets

Realistic session rates:

• Insurance reimbursement: $80–150 per session (varies by state/payer)
• Cash-pay: $150–300 per initial eval, $100–200 per follow-up

Volume targets (per week):

• Part-time (10 hours clinical): 10–15 patients
• Full-time (25 hours clinical): 25–40 patients

Annual revenue potential (full-time):

• Platform model (after fees): $100,000–180,000
• Solo practice (after marketing costs): $150,000–250,000+ (higher ceiling, but 2+ years to reach)

Your Next Step: Choose Your Path

You now understand the federal rules, your state’s specific requirements, the differences between psychiatrist and PMHNP practice, and the business realities of telehealth insomnia care.

If you’re a psychiatrist or PMHNP looking to start treating insomnia patients via telehealth without the risk of building from scratch: Explore joining Klarity Health’s provider network. You’ll get pre-qualified patients matched to insomnia treatment, handle all the regulatory complexity on the state-by-state basis, provide the telehealth infrastructure, and you pay only when you see patients. No marketing gambles, no upfront costs, no waiting 6 months for your first patient.

If you’re committed to building your own practice: Make sure you have realistic expectations about timeline (12+ months to sustainability), capital requirements ($10,000+ first year), and your own marketing expertise (or budget to hire experts). Start with one state, get your compliance foundation rock-solid, and build from there.

If you’re unsure which path fits: Consider starting with a platform to prove the concept, build your clinical skills in telehealth insomnia care, and generate income — then decide whether to expand into your own practice later.

The opportunity is real. Insomnia is massively undertreated, telehealth removes geographic barriers, and the regulations currently allow you to prescribe the medications patients need. But success requires navigating the regulatory maze correctly and choosing a business model that fits your risk tolerance and timeline.

The patients need help. The rules allow you to help them. Now it’s just about choosing your path forward.

Sources and References

1. DEA Press Release – ‘DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care’ (December 31, 2025) www.dea.gov — Official announcement of fourth temporary extension of telehealth prescribing rules through December 31, 2026.

2. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access’ (January 16, 2025) www.dea.gov — Details proposed permanent framework including Special Registration for telemedicine prescribing.

3. Healthcare Finance News – ‘Telehealth prescribing of controlled drugs extended through 2025’ by Susan Morse (November 18, 2024) www.healthcarefinancenews.com — Coverage of DEA extensions and Ryan Haight Act waiver history.

4. Florida Statutes §456.47 – Use of

Source:

• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=WASHINGTON%20%E2%80%93%C2%A0The%20U,flexibilities%20through%20December%2031%2C%202026
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=Under%20these%20telemedicine%20flexibilities%2C%20DEA,applicable%20federal%20and%20state%20law
• https://www.healthcarefinancenews.com/news/telehealth-prescribing-controlled-drugs-extended-through-2025#:~:text=During%20the%20COVID,person%20evaluation%20of%20that%20patient
• https://www.dlapiper.com/en-th/insights/publications/2024/11/dea-and-hhs-issue-third-temporary-extension-of-telemedicine-flexibilities#:~:text=Further%2C%20as%20the%20Third%20Temporary,monitor%20this%20space%20for%20updates
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=ever%20having%20an%20in,specialized%20medical%20providers%20to%20issue
• https://www.op.nysed.gov/professions/nurse-practitioners/professional-practice/practice-requirements#:~:text=New%20York%20State%20Education%20Law,to%20practice%20under%20physician%20supervision
• https://idfpr.illinois.gov/profs/nursing.html#:~:text=,APN%20Controlled%20Substance
• https://www.op.nysed.gov/professions/nurse-practitioners/professional-practice/practice-requirements#:~:text=Nurse%20practitioners%2C%20however%2C%20must%20practice,or%20certified%20NP%20as%20follows
• https://www.flsenate.gov/laws/statutes/2024/464.012#:~:text=also%20are%20psychiatric%20nurses%20as,455
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=provider%20may%20not%20use%20telehealth,in%20Schedule%20II%20of%20s